Jazz Pharmaceuticals plc (JAZZ)

127,73 -1,71 (-1,32%) Börsenschluss: 04:00PM EDT

Jazz Pharmaceuticals plc

Waterloo Exchange
Fifth Floor Waterloo Road
Dublin 4
Ireland
353 1 634 7800
https://www.jazzpharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 2.800

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Bruce C. Cozadd	Co-Founder, Chairman & CEO	2,45M	13,66M	1964
Mr. Daniel N. Swisher Jr.	Pres & COO	1,47M	N/A	1963
Ms. Renee D. Gala	Exec. VP & CFO	1,13M	N/A	1972
Dr. Robert Iannone M.D.	Exec. VP and Global Head of R&D	1,08M	N/A	1967
Ms. Kim Sablich M.B.A.	Exec. VP & GM of US	997,91k	N/A	1969
Ms. Patricia Carr	Sr. VP & Chief Accounting Officer	N/A	N/A	1971
Ms. Andrea N. Flynn Ph.D.	VP & Head of Investor Relations	N/A	N/A	N/A
Ms. Neena M. Patil J.D.	Exec. VP & Chief Legal Officer	N/A	N/A	1976
Dr. George Christopher Eliades Ph.D.	Sr. VP of Corp. Devel. & Chief Transformation Officer	N/A	N/A	1971
Ms. Heidi Manna	Sr. VP & Chief People Officer	N/A	N/A	1971

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Corporate Governance

Jazz Pharmaceuticals plcs ISS Governance QualityScore, Stand 28. September 2023, lautet 4. Die grundlegenden Scores sind Audit: 7, Vorstand: 3, Shareholderrechte: 3, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.